JPWO2021201087A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021201087A5
JPWO2021201087A5 JP2022534204A JP2022534204A JPWO2021201087A5 JP WO2021201087 A5 JPWO2021201087 A5 JP WO2021201087A5 JP 2022534204 A JP2022534204 A JP 2022534204A JP 2022534204 A JP2022534204 A JP 2022534204A JP WO2021201087 A5 JPWO2021201087 A5 JP WO2021201087A5
Authority
JP
Japan
Prior art keywords
seq
heavy chain
light chain
chain cdr
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022534204A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519776A5 (https=
JP7736688B2 (ja
JP2023519776A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2021/013795 external-priority patent/WO2021201087A1/en
Publication of JP2023519776A publication Critical patent/JP2023519776A/ja
Publication of JP2023519776A5 publication Critical patent/JP2023519776A5/ja
Publication of JPWO2021201087A5 publication Critical patent/JPWO2021201087A5/ja
Priority to JP2025141852A priority Critical patent/JP2025172866A/ja
Application granted granted Critical
Publication of JP7736688B2 publication Critical patent/JP7736688B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022534204A 2020-03-31 2021-03-31 多重特異性抗原結合分子を製造するための方法 Active JP7736688B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025141852A JP2025172866A (ja) 2020-03-31 2025-08-28 多重特異性抗原結合分子を製造するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020062601 2020-03-31
JP2020062601 2020-03-31
PCT/JP2021/013795 WO2021201087A1 (en) 2020-03-31 2021-03-31 Method for producing multispecific antigen-binding molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025141852A Division JP2025172866A (ja) 2020-03-31 2025-08-28 多重特異性抗原結合分子を製造するための方法

Publications (4)

Publication Number Publication Date
JP2023519776A JP2023519776A (ja) 2023-05-15
JP2023519776A5 JP2023519776A5 (https=) 2024-03-19
JPWO2021201087A5 true JPWO2021201087A5 (https=) 2024-03-19
JP7736688B2 JP7736688B2 (ja) 2025-09-09

Family

ID=77930118

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022534204A Active JP7736688B2 (ja) 2020-03-31 2021-03-31 多重特異性抗原結合分子を製造するための方法
JP2025141852A Pending JP2025172866A (ja) 2020-03-31 2025-08-28 多重特異性抗原結合分子を製造するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025141852A Pending JP2025172866A (ja) 2020-03-31 2025-08-28 多重特異性抗原結合分子を製造するための方法

Country Status (11)

Country Link
US (1) US20230121511A1 (https=)
EP (1) EP4126970A4 (https=)
JP (2) JP7736688B2 (https=)
KR (1) KR20220161375A (https=)
CN (1) CN115335410A (https=)
AU (1) AU2021250381A1 (https=)
BR (1) BR112022017526A2 (https=)
CA (1) CA3173519A1 (https=)
IL (1) IL296802A (https=)
MX (1) MX2022011387A (https=)
WO (1) WO2021201087A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI712421B (zh) 2013-11-11 2020-12-11 日商中外製藥股份有限公司 含改變的抗體可變區之抗原結合分子
TWI880146B (zh) 2014-11-11 2025-04-11 日商中外製藥股份有限公司 包含經改變之抗體可變區之抗原結合分子的資料庫
TW201938194A (zh) 2017-12-05 2019-10-01 日商中外製藥股份有限公司 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子
MX2021000827A (es) 2018-08-03 2021-03-25 Chugai Pharmaceutical Co Ltd Molecula de union a antigeno que contiene dos dominios de union a antigeno que estan enlazados entre si.
BR112021005472A2 (pt) 2018-09-28 2021-06-15 Chugai Seiyaku Kabushiki Kaisha molécula de ligação ao antígeno compreendendo uma região variável do anticorpo alterada
TWI909146B (zh) * 2020-03-31 2025-12-21 日商中外製藥股份有限公司 Dll3靶向之多特異性抗原結合分子及其用途
CN120265651A (zh) * 2022-11-25 2025-07-04 中外制药株式会社 用于生产蛋白质的方法
TW202506702A (zh) * 2023-04-07 2025-02-16 美商輝瑞股份有限公司 自同源二聚體抗體形成多特異性抗體之方法和包括自該方法得到的多特異性抗體之醫藥產物

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
DE4419399C1 (de) 1994-06-03 1995-03-09 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック,インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
CN100427603C (zh) 1999-10-04 2008-10-22 麦迪卡格公司 调控外源基因转录的方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005073732A2 (en) 2004-01-23 2005-08-11 Amgen Inc. Lc/ms method of analyzing high molecular weight proteins
JP5553963B2 (ja) 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド 組換え抗体をリフォールディングする方法
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
EP1925319B1 (en) 2005-06-10 2018-03-07 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(fv)2
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
US8337854B2 (en) 2007-04-04 2012-12-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Monoclonal antibodies against dengue and other viruses with deletion in Fc region
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP3907242A1 (en) 2010-01-29 2021-11-10 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antibody
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
PL2606064T3 (pl) 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
CA2817015A1 (en) * 2010-11-09 2012-05-18 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
RS67768B1 (sr) 2010-11-30 2026-03-31 Chugai Pharmaceutical Co Ltd Terapijski agens koji indukuje citotoksičnost
CN107266577B (zh) 2011-10-11 2022-09-13 弗·哈夫曼-拉罗切有限公司 双特异性抗体的改进的组装
CA2854233C (en) 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
PE20190658A1 (es) 2012-02-24 2019-05-08 Abbvie Stemcentrx Llc Moduladores y metodos de empleo novedosos
US20140072581A1 (en) 2012-07-23 2014-03-13 Zymeworks Inc. Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
TWI712421B (zh) * 2013-11-11 2020-12-11 日商中外製藥股份有限公司 含改變的抗體可變區之抗原結合分子
CN118440206A (zh) 2014-04-07 2024-08-06 中外制药株式会社 免疫活化抗原结合分子
TWI880146B (zh) * 2014-11-11 2025-04-11 日商中外製藥股份有限公司 包含經改變之抗體可變區之抗原結合分子的資料庫
CN107207607B (zh) 2014-12-19 2021-05-04 中外制药株式会社 抗-c5抗体及使用方法
TW201938194A (zh) * 2017-12-05 2019-10-01 日商中外製藥股份有限公司 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子
US11667713B2 (en) 2017-12-28 2023-06-06 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
MX2021000827A (es) * 2018-08-03 2021-03-25 Chugai Pharmaceutical Co Ltd Molecula de union a antigeno que contiene dos dominios de union a antigeno que estan enlazados entre si.
BR112021005472A2 (pt) * 2018-09-28 2021-06-15 Chugai Seiyaku Kabushiki Kaisha molécula de ligação ao antígeno compreendendo uma região variável do anticorpo alterada
KR20210068079A (ko) * 2018-09-28 2021-06-08 추가이 세이야쿠 가부시키가이샤 Cd3 및 cd137에 결합할 수 있지만 동시에는 결합하지 않는 항원 결합 분자
CN115175930A (zh) * 2020-02-05 2022-10-11 中外制药株式会社 用于产生和/或富集重组抗原结合分子的方法
TWI909146B (zh) * 2020-03-31 2025-12-21 日商中外製藥股份有限公司 Dll3靶向之多特異性抗原結合分子及其用途
WO2023053272A1 (en) * 2021-09-29 2023-04-06 Chugai Seiyaku Kabushiki Kaisha Uses of dll3-targeting multispecific antigen-binding molecules

Similar Documents

Publication Publication Date Title
JP2025111463A5 (https=)
JP2023078174A5 (https=)
US5541297A (en) Therapeutic conjugates of toxins and drugs
JP2023081303A5 (https=)
JPS61500789A (ja) モノクロ−ナル抗−ヒト乳癌抗体
JP2023071956A5 (https=)
JPWO2019175224A5 (https=)
JP2001506990A (ja) 一価の(monovalent)抗体フラグメント
JPWO2019224711A5 (https=)
JPS59116229A (ja) 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法
JP2540179B2 (ja) 非還元・非酵素的糖鎖形成蛋白に対するモノクロ―ナル抗体
JP2025183307A5 (https=)
JPWO2019175223A5 (https=)
JP2025138630A5 (https=)
JPS59116232A (ja) 細胞毒性複合体及びその製造法
JP2026053355A5 (https=)
US6136313A (en) Processes and intermediates for synthetic antibody derivatives
JP2011148820A (ja) 免疫グロブリンfabフラグメントを選択的且つ定量的に官能基化する方法
JP2025038088A5 (https=)
JPWO2021201087A5 (https=)
JPWO2019023564A5 (https=)
Dimasi et al. Generation of bispecific antibodies using chemical conjugation methods
JP2023530675A (ja) ヒト疾患の治療のためのcd38抗体
JPWO2020084115A5 (https=)
JPWO2021174113A5 (https=)